Montelukast%25252525252525252525252525252525252525252525252525252520levocetrizine

# Montelukast/Levocetirizine ## Overview Montelukast is a leukotriene receptor antagonist. Levocetirizine is a second-generation antihistamine. This combination is used for allergic rhinitis and chronic idiopathic urticaria. ## Primary Indications * Allergic Rhinitis (seasonal and perennial) * Chronic Idiopathic Urticaria ## Adult Dosing The typical dose for adults is montelukast 10 mg orally once daily combined with levocetirizine 5 mg orally once daily. Maximum dose: montelukast 10 mg once daily and levocetirizine 5 mg once daily. ## Pediatric Dosing Dosing depends on age and weight. * **Children 6 to 11 months:** Montelukast 4 mg orally once daily. (Levocetirizine is generally not recommended or established for this age group.) * **Children 1 to 5 years:** Montelukast 4 mg orally once daily and levocetirizine 1.25 mg orally once daily. * **Children 6 to 12 years:** Montelukast 5 mg orally once daily and levocetirizine 2.5 mg orally once daily. * **Adolescents 12 years and older:** Montelukast 10 mg orally once daily and levocetirizine 5 mg orally once daily. ## Dose Adjustments * **Hepatic Impairment:** A dose reduction of montelukast may be considered in patients with mild to moderate hepatic insufficiency. Levocetirizine dose adjustment is typically based on renal function. * **Renal Impairment:** For levocetirizine: * Mild impairment (CrCl 50-79 mL/min): No adjustment needed. * Moderate impairment (CrCl 30-49 mL/min): 2.5 mg orally once daily. * Severe impairment (CrCl <30 mL/min) and End-Stage Renal Disease: 2.5 mg orally every other day. * Hemodialysis: 2.5 mg orally every other day. * Montelukast does not typically require dose adjustment for renal impairment. ## Contraindications * Hypersensitivity to montelukast, levocetirizine, cetirizine, piperazine derivatives, or any component of the formulation. * Severe hepatic impairment (for montelukast). ## Adverse Effects Common: Somnolence (levocetirizine), headache, abdominal pain, diarrhea, influenza, rash, cough, fever, ear infection, upper respiratory infection. Serious: Neuropsychiatric events (montelukast, including suicidal ideation, depression, agitation, insomnia, hallucinations, aggressive behavior), hypersensitivity reactions (including anaphylaxis, angioedema, severe rash), Churg-Strauss syndrome (associated with montelukast). ## Key Drug Interactions * **CNS Depressants (e.g., sedatives, hypnotics, opioids, benzodiazepines):** Additive CNS depressant effects may occur with levocetirizine. * **Theophylline:** Montelukast may decrease the plasma concentration of theophylline; monitor theophylline levels. * **CYP1A2, CYP2C9, CYP3A4 Substrates:** Caution may be warranted with drugs metabolized by these enzymes as montelukast is metabolized by CYP enzymes, though significant interactions are uncommon. ## Monitoring * Monitor for neuropsychiatric changes in patients taking montelukast. Report any new or worsening symptoms of depression, suicidal thoughts, anxiety, agitation, or insomnia immediately. * Monitor for signs of hypersensitivity reactions. * Monitor renal function for levocetirizine dose adjustment. * If concomitant theophylline therapy, monitor theophylline levels. ## Clinical Pearls * Montelukast/levocetirizine is generally taken in the evening due to the potential for somnolence with levocetirizine. * Montelukast carries a boxed warning regarding neuropsychiatric events. Patients and caregivers should be advised of potential behavioral and mood changes. * Combination products may not offer flexible dosing for individual components if one agent is not needed or tolerated. * Always verify current prescribing information for the most up-to-date dosing, indications, and safety recommendations.